1. Home
  2. PWP vs NTLA Comparison

PWP vs NTLA Comparison

Compare PWP & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Perella Weinberg Partners

PWP

Perella Weinberg Partners

HOLD

Current Price

$21.69

Market Cap

1.2B

Sector

Finance

ML Signal

HOLD

Logo Intellia Therapeutics Inc.

NTLA

Intellia Therapeutics Inc.

HOLD

Current Price

$14.11

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PWP
NTLA
Founded
2006
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.6B
IPO Year
2020
2016

Fundamental Metrics

Financial Performance
Metric
PWP
NTLA
Price
$21.69
$14.11
Analyst Decision
Hold
Buy
Analyst Count
3
20
Target Price
$23.50
$20.45
AVG Volume (30 Days)
753.5K
2.9M
Earning Date
05-01-2026
05-07-2026
Dividend Yield
1.29%
N/A
EPS Growth
138.52
27.43
EPS
0.47
N/A
Revenue
N/A
$67,671,000.00
Revenue This Year
$31.87
N/A
Revenue Next Year
$16.54
$62.75
P/E Ratio
$45.87
N/A
Revenue Growth
N/A
16.92
52 Week Low
$14.99
$6.83
52 Week High
$25.93
$28.24

Technical Indicators

Market Signals
Indicator
PWP
NTLA
Relative Strength Index (RSI) 74.15 54.80
Support Level $20.70 $10.44
Resistance Level $23.01 $14.32
Average True Range (ATR) 0.80 0.82
MACD 0.51 0.15
Stochastic Oscillator 95.18 67.99

Price Performance

Historical Comparison
PWP
NTLA

About PWP Perella Weinberg Partners

Perella Weinberg Partners is an independent advisory firm that provides strategic and financial advice to a wide range of clients. The Company's activities as an investment banking advisory firm constitute a single business segment that provides a range of advisory services, including advice related to strategic and financial decisions, mergers and acquisitions execution, shareholder and defense advisory, financing and capital solutions advice with resources focused on restructuring and liability management, capital markets advisory, private capital placement, as well as specialized underwriting and research services for the energy and related industries.

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Share on Social Networks: